Profile: Infinity Pharmaceuticals Inc (INFI.O)
29 Jul 2016
Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology.
The Company's products in development include DYNAMO, which is indicated for the Refractory indolent non-Hodgkin lymphoma; CONTEMPO, which is indicated for the Previously untreated follicular lymphoma; BRAVURA, which is indicated for the Relapsed indolent non-Hodgkin lymphoma; FRESCO, which is indicated for the Relapsed or refractory follicular lymphoma; DYNAMO+R, which is indicated for the Previously treated follicular lymphoma; DUO, which is indicated for the Relapsed or refractory chronic lymphocytic leukemia, and SYNCHRONY is indicated for the Patients with chronic lymphocytic leukemia whose disease has progressed following treatment with a Bruton's tyrosine kinase inhibitor. The Company's Duvelisib + Venetoclax are indicated for Relapsed or refractory indolent or aggressive non-Hodgkin lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma.
The Company competes with Gilead Sciences, Inc., Bayer AG, TG Therapeutics, Inc., Novartis AG, Acerta Pharma BV, Genentech, Incyte Corporation, Rhizen Pharmaceuticals S.A., Pharmacyclics, Inc., AbbVie, Celgene Corporation, Acerta Pharma BV, Incyte Corporation, MorphoSys, BeiGene Co., Ltd, Bristol-Myers Squibb Company, Roche Group and AstraZeneca PLC.
Infinity Pharmaceuticals Inc
784 Memorial Dr
CAMBRIDGE MA 02139-4613
Company Web Links
- BRIEF-Infinity Pharmaceuticals sees workforce restructuring completed by year-end
- BRIEF-Infinity regains worldwide rights to duvelisib; ends collaboration with AbbVie
- BRIEF-Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln
- BRIEF-Infinity Pharmaceuticals Inc reports topline results from DYNAMO(tm)
- BRIEF-Infinity Pharmaceuticals reports Q1 loss per share $0.82